Experiments show fecal transplants from successful immunotherapy patients to non-responders transferred the ability to respond to treatment, improving outcomes in melanoma trials.
Clinical trials led by oncologists in Pennsylvania and Israel saw promising results with FMT, benefiting a significant portion of participants who had previously not responded to immunotherapy.
Collection
[
|
...
]